GranulesIndiaEarnsGoldRatinginFirst-EverCorporate-LevelEcoVadisAssessment Ranks in the Top 5% Globally Across All Industries
Mumbai,India –May7,2025:GranulesIndiaLimited(BSE:532482,NSE:GRANULES), a vertically integrated pharmaceutical company committed to sustainable and responsible healthcare, has been awarded a Gold rating by EcoVadis in its inaugural corporate-level assessment. This places the company in the 97th percentile, among thetop 5% of all companies assessed globally across all industries.
EcoVadis isone of the world’s trusted providers of business sustainability ratings, assessing companiesonenvironment,labour&humanrights,ethics,andsustainableprocurement.This recognition affirms Granules’robust sustainability practices and transparency in its business operations.
The company’s first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence across its manufacturing footprint. The rating reflects the company’s purpose-driven transformation journey — Healing lives responsibly throughpioneeringgreenscience —andalignswithitsbroadersustainabilitygoals,including science-based climate targets, greener chemistry platforms, and safer workplace practices.
“This Gold rating is more than a recognition — it’s a reminder that we are choosing to grow differently by placing sustainability at the heart of our progress,” said Dr. Krishna Prasad Chigurupati,ChairmanandManagingDirectorofGranulesIndia.“Itisamomentofpride,but also one of responsibility to continue raising the bar as we build a more resilient and responsible future.”
PriyankaChigurupati,ExecutiveDirector,added:“Wedeeplyvaluethetrustandpartnership of our customers and suppliers. This milestone is a shared win — a testament to what’s possible when we act together with ‘One Planet, One Purpose’.”
AboutGranulesIndiaLtd.(BSE:532482,NSE:GRANULES)
Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitmenttooperationalexcellence,quality,andcustomerservice.Granulesisamongthe fewpharmaceuticalcompaniesintheworldtobepresentinthemanufacturingofentirevalue chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Granules products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over80+ countrieswithofficesacross India, US, and UK. The Company has10 manufacturing facilities out of which 8 are in India and 2 in the USA and has regulatory approvalsfromUSFDA,EDQM,EUGMP,COFEPRIS,WHOGMP,TGA,KFDA,DEA,MCC,
and HALAL.
|
MediaContact:
PriyankaChawla Manager-CorporateCommunications priyanka.chawla@granulesindia.com |
InvestorsContact:
ChaitanyaTummala Company Secretary investorrelations@granulesindia.com |
Post a Comment